93 related articles for article (PubMed ID: 11082720)
1. [Pharmacology of platinum analogs-taxanes interactions].
Boisdron-Celle M; Gamelin E
Bull Cancer; 2000 Aug; 87 Spec No():30-3. PubMed ID: 11082720
[TBL] [Abstract][Full Text] [Related]
2. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.
Calvert AH
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-85-S2-90. PubMed ID: 9045345
[TBL] [Abstract][Full Text] [Related]
3. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy.
Kearns CM; Egorin MJ
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-91-S2-96. PubMed ID: 9045346
[TBL] [Abstract][Full Text] [Related]
4. [Carboplatin in cancer of the ovary].
Pujade-Lauraine E; Guastalla JP; Vincent P
Bull Cancer; 2000 Aug; 87 Spec No():40-7. PubMed ID: 11082722
[TBL] [Abstract][Full Text] [Related]
5. Drug interactions with the taxanes.
Baker SD
Pharmacotherapy; 1997; 17(5 Pt 2):126S-132S. PubMed ID: 9322879
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions with the taxanes: clinical implications.
Baker AF; Dorr RT
Cancer Treat Rev; 2001 Aug; 27(4):221-33. PubMed ID: 11545542
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
12. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Kobayashi H; Eckhardt SG; Lockridge JA; Rothenberg ML; Sandler AB; O'Bryant CL; Cooper W; Holden SN; Aitchison RD; Usman N; Wolin M; Basche ML
Cancer Chemother Pharmacol; 2005 Oct; 56(4):329-36. PubMed ID: 15906031
[TBL] [Abstract][Full Text] [Related]
15. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Chang HM; Kim TW; Ryu BY; Choi SJ; Park YH; Lee JS; Kim WK; Kang YK
Jpn J Clin Oncol; 2005 May; 35(5):251-5. PubMed ID: 15886269
[TBL] [Abstract][Full Text] [Related]
20. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
Nagao S; Okimoto N; Hongo A; Mizutani Y; Kodama J; Yoshinouchi M; Hiramatsu Y; Kudo T
Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
